Business Wire

1E

Share
1E doubles down for massive growth in DEX category with leadership transformation focused on Customer Success, Product, Technology and Sales

1E , the leader in Digital Employee Experience (DEX), today appointed six new senior leaders in response to booming growth in the DEX category as organizations increasingly prioritize supporting the hybrid and remote work needs of employees.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005732/en/

“2022 is going to be an epic year for 1E. We start the year on the heels of our biggest quarter ever and the launch of the latest generation of our SaaS Digital Employee Experience platform, 1E Tachyon. We've also seen significant tailwinds as DEX has become a major boardroom priority as a way to understand employee engagement, happiness and productivity in uncertain times” said Mark Banfield, CEO of 1E. “These new appointments, half of whom are women, are a key piece of the puzzle in our aggressive growth strategy and will propel us to new heights as we lead the way in writing DEX history.”

Building an organization acutely focused on customer success was paramount to 1E’s business transformation. This new approach puts 1E customers at the center so that they are better equipped to support and improve the digital experience of their employees. 1E is also doubling down on product and technology. These new additions are reflective of this strategy.

New appointments include:

● Marie Palmer, Chief Customer Officer

● Ian Van Reenen, Chief Technology Officer

● Amy Collins, Senior Vice President, Product

● Alice Carlisle, Vice President, Sales for EMEA

● Lucas Ryder, Vice President, Sales for North America

● Jason Keogh, Field CTO

Marie Palmer joins as 1E’s Chief Customer Officer. Marie, who has over fifteen years of experience leading customer success teams, the last six of which were devoted to leading customer success for VMWare in EMEA and APAC.

Ian Van Reenen joins 1E as Chief Technology Officer. Ian, a veteran technologist, has over 20 years’ experience building products to help IT departments offer a more secure, efficient, and better service at companies such as Datto, Autotask and CentraStage.

Amy Collins has been promoted to Senior Vice President, Product. Amy has worked in the technology sector for 20 years and has spent most of this time in product roles building software products in fast growth, disruptive technology companies such as Brandwatch and Signal AI.

Alice Carlisle and Lucas Ryder join as Vice President of Sales for EMEA and North America respectively. Carlisle joins most recently from LogicMonitor, where she achieved significant growth in EMEA sales, and Ryder joins from Darktrace, where he ran sales in North America. Both worked together previously at Autotask and Datto.

Jason Keogh has been promoted to Field CTO to help 1E customers map their DEX requirements back to technology solutions and to build a feedback loop between the customer base and product team. Prior to joining 1E, Jason was founder and CTO of iQuate.

About 1E

1E are the innovators in Digital Employee Experience (DEX) that supports the work from anywhere enterprise, so employees are secure, supported, and productive wherever they want to be. The 1E Tachyon Platform provides real-time diagnosis, remediation and automation that fixes issues, fast and without interruption. It puts employees in control, through self-service, self-heal and sentiment monitoring to understand how they really feel and reduces help desk calls and ultimately costs. That’s why more than 500 organizations in 42 countries trust 1E to help them manage 11 million endpoints seamlessly. For more information, visit www.1E.com .

###

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release

Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M

Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release

Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release

Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep

ViaLase Announces Strategic Leadership Transitions to Support Commercial Growth8.7.2025 14:00:00 CEST | Press release

ViaLase, Inc., a medical technology company pioneering noninvasive femtosecond laser treatments for glaucoma, today announced key changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to the role of President and Chief Technology Officer, where he will continue to guide the company’s technological innovation roadmap. Shawn O’Neil, most recently Chief Commercial Officer, has been appointed Chief Executive Officer. In turn, Pete England has been promoted to Chief Commercial Officer. “These leadership changes mark an important milestone in ViaLase’s evolution,” said Tom Frinzi, Executive Chairman of the Board. “Tibor has done an extraordinary job building a world-class R&D and clinical organization, laying the foundation for what promises to be a major advancement in glaucoma care. His track record as an entrepreneu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye